Shots:

• The first patient has been dosed in a P-I clinical study to compare the PK and safety of BAT2206- a proposed biosimilar to Stelara (ustekinumab) to US/EU-sourced reference product in healthy volunteers
• The company is expected to enroll 270 healthy volunteers. BAT2206 represents the fifth biosimilar of Bio-Thera’s portfolio that has advanced into clinical development
• BioThera is developing additional products- including QLETLI (biosimilar to Humira)- which is approved in China- BAT1706 (biosimilar to Avastin)- that has completed a P-III study with expected regulatory submission in Q4’20. The company is also pursuing biosimilar versions of Actemra- Cosentyx- and Simponi

­ Ref: BioThera | Image: Long Term Care Rx